Epstein Secrets

imers. The discovery is critical, explains Dr. Bin Zhang, a co-lead author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. Because we can now "evaluate drugs that impact the TREM2-TYROBP pathway as potential therapies... and design more specific compounds that target th

onset of late Alzheimers. The discovery is critical, explains Dr. Bin Zhang, a co-lead author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. Because we can now "evaluate drugs that impact the TREM2-TYROBP pathway as potential therapies... and design more specific compounds

zheimer's. The discovery is critical, Dr. Bin Zhang explained, a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TFtEM2- TYROBP pathway as potential therapies... and design more specific compounds that target these key

ntly connected to Alzheimer's. The discovery is critical, Dr. Bin Zhang explained, a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TFtEM2- TYROBP pathway as potential therapies... and design more specific compounds that t

zheimer's. The discovery is critical, Dr. Bin Zhang explained, a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TREM2- TYROBP pathway as potential therapies... and design more specific compounds that target these key

ntly connected to Alzheimer's. The discovery is critical, Dr. Bin Zhang explained, a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TREM2- TYROBP pathway as potential therapies... and design more specific compounds that ta

imers. The discovery is critical, explains Dr. Bin Zhang, a co-lead author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. Because we can now "evaluate drugs that impact the TREM2-TYROBP pathway as potential therapies... and design more specific compounds that target th

onset of late Alzheimers. The discovery is critical, explains Dr. Bin Zhang, a co-lead author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. Because we can now "evaluate drugs that impact the TREM2-TYROBP pathway as potential therapies... and design more specific compounds